PharmaEngine, Inc. (TPEX:4162)

Market Cap	10.11B
Revenue (ttm)	2.51B
Net Income (ttm)	1.67B
Shares Out	143.68M
EPS (ttm)	11.63
PE Ratio	6.05
Forward PE	26.00
Dividend	6.00 (8.52%)
Ex-Dividend Date	Aug 13, 2025

Volume	247,658
Average Volume	426,736
Open	70.20
Previous Close	70.10
Day's Range	70.00 - 71.00
52-Week Range	63.90 - 123.00
Beta	0.18
RSI	44.36
Earnings Date	Mar 12, 2026

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 44
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4162

Financial Performance

In 2024, PharmaEngine's revenue was 2.52 billion, an increase of 228.70% compared to the previous year's 767.67 million. Earnings were 1.75 billion, an increase of 537.55%.